铜减轻了帕金森病模型中的阿特拉诱导的神经毒性
Bingyun Li1, Ruijiao Yang2, Xiaojuan Chen1
1School of Public Health, Shantou University, Shantou, 515063, Guangdong Province, China.
Molecular neurobiology
|November 11, 2024
概括
暴露于阿特拉津除草剂会破坏金属平衡并损害大脑细胞,可能会恶化帕金森病. 补充铜可以抵消这些影响,恢复金属平衡并改善大鼠的运动功能.
科学领域:
- 环境毒理学环境毒理学
- 神经科学是一个神经科学.
- 金属与健康的关系
背景情况:
- 阿特拉 (ATR) 是一种广泛使用的除草剂,与神经退行性疾病有关.
- 金属稳态在神经退行性疾病的病理生理学中至关重要.
- 帕金森病 (PD) 涉及多巴胺能神经元退化.
研究的目的:
- 研究铜补充剂对ATR诱导的神经毒性的神经保护作用.
- 为了检查ATR对铜和铁恒温的影响,在黑色物质的密集部分 (SNpc).
- 评估金属失调在ATR对PD病理学的贡献中的作用.
主要方法:
- 使用了对帕金森病的老鼠模型.
- 暴露于阿特拉辛 (ATR) 的老鼠.
- 管理的铜补充剂.
- 在SNpc.中分析金属稳态 (铜和铁).
- 测量了氧化应激标志物和多巴胺能神经元完整性.
- 评估运动功能.
主要成果:
- 在SNPc中,ATR暴露破坏了铜和铁的平衡.
- ATR导致氧化应激增加和多巴胺能神经元损失.
- 铜补充恢复了SNPc中的金属平衡.
- 铜治疗降低了PD大鼠的脂质过氧化和改善了运动功能.
结论:
- 由于ATR引起的金属平衡的破坏,有助于与PD相关的神经退行.
- 铜补充剂对ATR毒性产生神经保护作用.
- 准金属稳态可能为环境毒素诱导的神经退行性疾病提供治疗策略.
更多相关视频
06:17Quantifying Levels of Dopaminergic Neuron Morphological Alteration and Degeneration in Caenorhabditis elegans
Published on: November 20, 2021
4.1K
16:21Quantifying Fish Swimming Behavior in Response to Acute Exposure of Aqueous Copper Using Computer Assisted Video and Digital Image Analysis
Published on: February 26, 2016
11.1K
相关概念视频
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
